IL308219A - Compounds for targeting degradation of bruton's tyrosine kinase - Google Patents
Compounds for targeting degradation of bruton's tyrosine kinaseInfo
- Publication number
- IL308219A IL308219A IL308219A IL30821923A IL308219A IL 308219 A IL308219 A IL 308219A IL 308219 A IL308219 A IL 308219A IL 30821923 A IL30821923 A IL 30821923A IL 308219 A IL308219 A IL 308219A
- Authority
- IL
- Israel
- Prior art keywords
- bruton
- compounds
- tyrosine kinase
- targeting degradation
- targeting
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 230000015556 catabolic process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184439P | 2021-05-05 | 2021-05-05 | |
| PCT/US2022/027888 WO2022235945A1 (en) | 2021-05-05 | 2022-05-05 | Compounds for targeting degradation of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308219A true IL308219A (en) | 2024-01-01 |
Family
ID=82115630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308219A IL308219A (en) | 2021-05-05 | 2022-05-05 | Compounds for targeting degradation of bruton's tyrosine kinase |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240287076A1 (en) |
| EP (1) | EP4333899A1 (en) |
| JP (1) | JP2024519496A (en) |
| KR (1) | KR20240017814A (en) |
| CN (1) | CN117580592A (en) |
| AR (1) | AR125768A1 (en) |
| AU (1) | AU2022268977A1 (en) |
| BR (1) | BR112023023065A2 (en) |
| CA (1) | CA3217417A1 (en) |
| CL (1) | CL2023003258A1 (en) |
| CO (1) | CO2023016743A2 (en) |
| IL (1) | IL308219A (en) |
| MX (1) | MX2023013046A (en) |
| TW (1) | TW202309039A (en) |
| UY (1) | UY39756A (en) |
| WO (1) | WO2022235945A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US20150291562A1 (en) | 2014-04-14 | 2015-10-15 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| EP3256470B1 (en) | 2014-12-23 | 2023-07-26 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| AU2016209349B2 (en) | 2015-01-20 | 2020-05-07 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the Androgen Receptor |
| CA2979070A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| JP6873433B2 (en) | 2015-06-04 | 2021-05-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | Imid modifiers for proteolysis and related uses |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2988430A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
| KR20180029061A (en) | 2015-07-13 | 2018-03-19 | 아비나스 인코포레이티드 | Alanine regulators of protein degradation and related uses |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| UA123786C2 (en) | 2016-04-06 | 2021-06-02 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Mdm2 protein degraders |
| EP3442976B1 (en) | 2016-04-12 | 2022-07-20 | The Regents of The University of Michigan | Bet protein degraders |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| HUE061847T2 (en) | 2016-10-11 | 2023-08-28 | Arvinas Operations Inc | Compounds and methods for the targeted degradation of androgen receptor |
| CA3042260C (en) | 2016-11-01 | 2023-10-03 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| RU2750484C2 (en) | 2016-12-01 | 2021-06-28 | Эрвинэс Оперейшнс, Инк. | Derivatives of tetrahydronaphtalene and tetrahydroisoquinoline as deconstructors of estrogen receptor |
| CN117510491A (en) | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| BR112019012682A2 (en) | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | chimeric molecules targeting egfr proteolysis and associated methods of use |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| UY37559A (en) * | 2017-01-06 | 2018-05-31 | Pharmacyclics Llc | PIRAZOLO [3,4-B] PIRIDINE AND PIRROLO [2,3-B] PIRIDINE AS INHIBITORS OF BRUTON TYPOSINE KINASE |
| KR102582886B1 (en) | 2017-01-26 | 2023-09-26 | 아비나스 오퍼레이션스, 인코포레이티드 | Estrogen receptor proteolysis regulators and related methods of use |
| BR112019015484A2 (en) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | cereblon ligands and bifunctional compounds comprising the same |
| US20180353501A1 (en) | 2017-06-09 | 2018-12-13 | Arvinas, Inc. | Modulators of proteolysis and associated methods of use |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN111212835A (en) | 2017-07-28 | 2020-05-29 | 阿尔维纳斯运营股份有限公司 | Compounds and methods for targeted degradation of androgen receptors |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019186343A1 (en) * | 2018-03-26 | 2019-10-03 | Novartis Ag | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| CN111936501B (en) * | 2018-03-26 | 2023-09-22 | 诺华股份有限公司 | Bruton's tyrosine kinase degradation agent |
| SG11202008898UA (en) | 2018-04-01 | 2020-10-29 | Arvinas Operations Inc | Brm targeting compounds and associated methods of use |
| IL302595A (en) | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| AU2020272978A1 (en) | 2019-04-12 | 2021-09-16 | C4 Therapeutics, Inc. | Tricyclic degraders of Ikaros and Aiolos |
| WO2021053495A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Bifunctional degraders and their methods of use |
| JP2023501238A (en) * | 2019-10-30 | 2023-01-18 | バイオジェン・エムエイ・インコーポレイテッド | Fused pyridazines or pyrimidines as Btk inhibitors |
| EP4051680A1 (en) * | 2019-10-30 | 2022-09-07 | Biogen MA Inc. | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| CN116194453A (en) | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | Protein tyrosine phosphatase degrading agent and method of use thereof |
| AU2021264916A1 (en) * | 2020-04-30 | 2022-11-03 | Beigene, Ltd. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
-
2022
- 2022-05-05 IL IL308219A patent/IL308219A/en unknown
- 2022-05-05 WO PCT/US2022/027888 patent/WO2022235945A1/en active Application Filing
- 2022-05-05 US US18/289,438 patent/US20240287076A1/en active Pending
- 2022-05-05 KR KR1020237041952A patent/KR20240017814A/en unknown
- 2022-05-05 EP EP22731839.1A patent/EP4333899A1/en active Pending
- 2022-05-05 AR ARP220101179A patent/AR125768A1/en unknown
- 2022-05-05 BR BR112023023065A patent/BR112023023065A2/en unknown
- 2022-05-05 JP JP2023567962A patent/JP2024519496A/en active Pending
- 2022-05-05 MX MX2023013046A patent/MX2023013046A/en unknown
- 2022-05-05 AU AU2022268977A patent/AU2022268977A1/en active Pending
- 2022-05-05 UY UY0001039756A patent/UY39756A/en unknown
- 2022-05-05 CA CA3217417A patent/CA3217417A1/en active Pending
- 2022-05-05 CN CN202280047793.5A patent/CN117580592A/en active Pending
- 2022-05-05 TW TW111116998A patent/TW202309039A/en unknown
-
2023
- 2023-11-02 CL CL2023003258A patent/CL2023003258A1/en unknown
- 2023-12-01 CO CONC2023/0016743A patent/CO2023016743A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202309039A (en) | 2023-03-01 |
| CL2023003258A1 (en) | 2024-05-03 |
| KR20240017814A (en) | 2024-02-08 |
| EP4333899A1 (en) | 2024-03-13 |
| BR112023023065A2 (en) | 2024-01-30 |
| JP2024519496A (en) | 2024-05-14 |
| CO2023016743A2 (en) | 2023-12-29 |
| US20240287076A1 (en) | 2024-08-29 |
| CA3217417A1 (en) | 2022-11-10 |
| UY39756A (en) | 2022-11-30 |
| WO2022235945A1 (en) | 2022-11-10 |
| AR125768A1 (en) | 2023-08-09 |
| CN117580592A (en) | 2024-02-20 |
| AU2022268977A1 (en) | 2023-11-30 |
| MX2023013046A (en) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY147628A (en) | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| SI2054418T1 (en) | Dihydrothieno pyrimidines as akt protein kinase inhibitors | |
| CR20200358A (en) | Compounds for the treatment of kinase-dependent disorders | |
| IN2014KN02886A (en) | ||
| MX2009014013A (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors. | |
| WO2009006567A3 (en) | Pyrimidyl cyclopentanes as akt protein kinase inhibitors | |
| EA201070012A1 (en) | METABOLITES for (R) -3- (4- (7H-PYRROLO [2,3-d] PYRIMIDIN-4-IL) -1H-Pyrazol-1-IL) -3-CYCLOPENTYL-PROPHANITRIL, JANUS KINAZ INHIBITOR | |
| WO2008094909A3 (en) | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions | |
| WO2010045251A3 (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
| EP2134346A4 (en) | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 | |
| GEP20247638B (en) | Pharmaceutical combination of prmt5 inhibitors | |
| IL261249B1 (en) | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | |
| ATE493418T1 (en) | DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS | |
| MX2022014351A (en) | Compounds for the treatment of kinase-dependent disorders. | |
| EA201200875A1 (en) | SPHINGOZINKINASE INHIBITORS | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| IL284916A (en) | Cyclic molecules as bruton's tyrosine kinase inhibitor | |
| IL308219A (en) | Compounds for targeting degradation of bruton's tyrosine kinase | |
| EP3882241A4 (en) | Inhibitor of bruton's tyrosine kinase | |
| IL314260A (en) | Pyrimidines for degrading bruton's tyrosine kinase | |
| IL314902A (en) | Synthesis of bruton's tyrosine kinase inhibitors | |
| EP4069689A4 (en) | Substituted imidazolecarboxamide as bruton's tyrosine kinase inhibitors | |
| IL312743A (en) | Compounds targeting pmp22 for the treatment of charcot-marie-tooth disease | |
| EP4208262A4 (en) | Targeting enhancer rnas for the treatment of primary brain tumors | |
| GB202103176D0 (en) | Pyrroloquinoline compounds as modulators of Bruton's tyrosine kinase (BTK). |